|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Hematology,Nephrology,and Rheumatology |
|
Date of Birth |
1964 |
|
Laboratory Address |
Dept. Hematology, Akita Univ. |
|
Laboratory Phone number |
+81-18-884-6115 |
|
Laboratory Fax number |
+81-18-836-2613 |
|
Mail Address |
|
TAKAHASHI Naoto
|
|
|
Research Interests 【 display / non-display 】
-
血液腫瘍学
-
分子細胞遺伝学
-
薬物動態
-
薬物遺伝学
-
血液学
Graduating School 【 display / non-display 】
-
-1997
Akita University Graduated
-
-1997
Akita University Graduated
-
-1990.03
Akita University Faculty of Medicine Graduated
-
-1990
Akita University Faculty of Medicine Graduated
-
-1990
Akita University Faculty of Medicine School of Medicine Graduated
Graduate School 【 display / non-display 】
-
-1997.03
Akita University Graduate School,Division of Medicine Doctor's Course Completed
Studying abroad experiences 【 display / non-display 】
-
2003.05-2005.09
Saskatoon Cancer Centre, University of Saskatchewan Postdoctoral Research Fellowship
Campus Career 【 display / non-display 】
-
2015.02-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Professor
-
2006.04-2015.01
Akita University School of Medicine School of Medicine Lecturer
External Career 【 display / non-display 】
-
2015.02
Akita University Graduate School of Medicine Professor
Research Areas 【 display / non-display 】
-
Life Science / Hematology and medical oncology
-
Life Science / Hematology and medical oncology
Research Achievements 【 display / non-display 】
-
Ayano Saito, Yoshihiro Kameoka, Kumi Ubukawa, Hiroshi Ohtani, Fumito Abe, Masaya Saito, Mako Hashimoto, Tatsuro Kanazawa, Atsushi Komatsuda, Naoto Takahashi
Internal medicine (Tokyo, Japan) ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 2024.10
Research paper (journal)
A 71-year-old woman developed nephrotic syndrome during 10-year follow-up for chronic lymphocytic leukemia. A renal biopsy sample analysis revealed IgG1-lambda-positive monoclonal immunotactoid glomerulopathy (mITG). The patient was treated with ibrutinib, a Bruton tyrosine kinase inhibitor, and complete renal remission was achieved after 24 months. ITG is a rare disease that is characterized by glomerular deposition. In particular, mITG, which presents immune deposits that exhibit light-chain restriction, is often associated with hematologic disorders. Most patients with mITG receive immunosuppressive therapy and/or chemotherapy; however, to our knowledge, there have been no reports of treatment with ibrutinib.
-
Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study.
Nagi Tozawa, Takaya Yamashita, Miho Nara, Yuki Fujioka, Sho Ikeda, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi
Cureus 15 ( 12 ) e50416 2023.12
Research paper (journal)
Introduction The overall survival (OS) of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) has improved with the combination of tyrosine kinase inhibitor (TKI) with intensive chemotherapy. In recent years, there has been increased interest in the possibility of long-term survival without allogeneic hematopoietic stem cell transplantation (HSCT) or maintenance therapy. The aim of this study was to determine the effectiveness of treatment and the resultant outcomes in Ph+ALL patients using real-world data. Methods We performed a single-center retrospective analysis utilizing Akita University Hospital data (Akita, Japan) from November 2000 to June 2023 to evaluate the outcomes of TKI with intensive chemotherapy for Ph+ALL. Results Twenty-three patients with Ph+ALL were treated with intensive chemotherapy combined with TKI, including six imatinib, four dasatinib, and 13 ponatinib. The median patient age was 53 years (range; 28-67). Eighteen patients (78%) achieved complete molecular remission (CMR) within three months. HSCT was performed in 16 patients (70%), all of whom did not receive post-transplant TKI maintenance therapy. Six of the seven patients who did not undergo HSCT received maintenance therapy with ponatinib after intensive chemotherapy. The three-year OS was 81%. Ponatinib treatment resulted in a much higher OS rate than imatinib/dasatinib (100% vs. 60%; P=0.011). CMR within three months was identified as a prognostic factor for molecular relapse-free survival (hazard ratio (HR)=0.22; P=0.027). CD20 positivity was identified as a risk factor for hematological relapse (HR=5.2, P=0.032). Conclusion Even in a single-center cohort study, ponatinib, as a combination TKI with intensive chemotherapy or maintenance therapy, may improve the prognosis of Ph+ALL. Patients with CMR within three months might not necessarily need to receive HSCT, but a subsequent treatment-free status could have been achieved only by HSCT. Furthermore, CD20 positivity may be a useful biomarker for future treatment decisions in patients with Ph+ALL.
-
Abumiya M.
Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics ) 46 ( 2 ) 382 - 387 2021.04 [Refereed]
Research paper (journal) Domestic Co-author
-
Abumiya M.
Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics ) 46 ( 1 ) 219 - 222 2021.02 [Refereed]
Research paper (journal) Domestic Co-author
-
Ito F.
International Journal of Hematology ( International Journal of Hematology ) 113 ( 1 ) 100 - 105 2021.01 [Refereed]
Research paper (journal) Domestic Co-author
-
Kumagai Takuya, Saito Masaya, Sato Takahiko, Inoue Junichi, Ishikawa Norihisa, Ono Tsuyoshi, Kono Michihiro, Takahashi Naoto
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 2025
<p>We herein report a case of cutaneous squamous cell carcinoma (SCC) characterized by paraneoplastic hypercalcemia-leukocytosis syndrome. The patient presented with systemic symptoms, including anorexia, a fever, and a tumoral lesion on the upper arm. Laboratory test results revealed hypercalcemia and leukocytosis. A tissue biopsy confirmed SCC, and further investigation revealed elevated parathyroid hormone-related protein (PTHrP) and granulocyte-colony stimulating factor (G-CSF) levels. Immunostaining demonstrated G-CSF production by the tumor cells. Radiation therapy was administered, which improved leukocytosis and decreased G-CSF and PTHrP levels. Through a case report and literature review, we explored the clinical characteristics of tumors that produce G-CSF and PTHrP. </p>
-
LINC00887はHDAC3との結合を介して多発性骨髄腫細胞の薬剤耐性を誘導する
長田 直希, 松岡 紗恵, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 1 2024.10
-
SETD7はt(11;14)陽性多発性骨髄腫に対する新たな治療標的分子となる
松岡 紗恵, 長田 直希, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 4 2024.10
-
TFR後の晩期再発は免疫の調節不全を背景にしている
藤岡 優樹, 植木 重治, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 5 2024.10
-
7. Progress in the Treatment of CML
Takahashi Naoto
Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine ) 113 ( Suppl ) 120a - 120a 2024.02
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
The mechanism of organelle relocation in human erythroblasts.
Grant-in-Aid for Scientific Research(C)
Project Year： 2018.04 - 2022.03 Investigator(s): Ubukawa Kumi
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2018.04 - 2022.03
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2014.04 - 2018.03
-
Do patients taking tacrolimus need to undergo CYP3A5 genotyping along with blood concentration monitoring?
Grant-in-Aid for Scientific Research(C)
Project Year： 2014.04 - 2018.03 Investigator(s): Niioka Takenori, MIURA Masatomo, SATOH Shigeru, TAKAHASHI Naoto, KAGAYA Hideaki
-
Development of a new treatment strategy using TDM for next generation anticancer drug
Grant-in-Aid for Scientific Research(C)
Project Year： 2014.04 - 2017.03 Investigator(s): Miura Masatomo, Takahashi Naoto, Shibata Hiroyuki, Tsuchiya Norihiko, Kagaya Hideaki, Abumiya Maiko
Acceptance of contract business 【 display / non-display 】
-
Contract period： 2020.04.01 - 2021.03.31
-
Contract period： 2020.04.01 - 2021.03.31
-
Contract period： 2020.04.01 - 2021.03.31